



New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges

Guest Editor:

Dr. Ahmed Bakillah

King Abdullah International
Medical Center (KAIMRC), Eastern
Region, King Saud Bin Abdul-Aziz
University of Health Sciences,
Ministry of National Guards-
Health Affairs, Mail Code 520, P.O.
Box 6664, AL Asha 31982, Saudi
Arabia

Deadline for manuscript
submissions:

closed (31 December 2018)

Message from the Guest Editor

Dear Colleagues,

Remarkable research efforts have been made in lowering plasma cholesterol levels by the widespread use of statins resulting in significant reduction of death rate by ~30%–40%. Despite all these efforts, cardiovascular disease (CVD) continue to be the leading cause of mortality worldwide. After recent failure with cholesteryl ester transfer protein inhibitors, effective lipid lowering drugs emerged as new revolutionizing lipid-lowering therapy. In this context, human anti-PCSK9 antibodies have been shown in a wide range of patients, including those with statins intolerance, to significantly decrease plasma cholesterol by ~50%–70% with no alarming safety signals.

This Special Issue will provide an open access opportunity to publish research work and review articles related to recent advances in the field of CVD, new molecular insights and potential therapeutic strategies for better patient diagnosis and disease prevention.

Dr. Ahmed Bakillah

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment
—FROG Research Group,
University of Valencia, 46010
Valencia, Spain

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental)

Contact Us

Diseases Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/diseases
diseases@mdpi.com
X@Diseases_MDPI